United Kingdom· GB-APID-38373411000001100
Kadcyla 100mg powder for concentrate for solution for infusion vials
A trastuzumab emtansine product containing trastuzumab emtansine, registered in United Kingdom by Originalis B.V.. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Trastuzumab emtansine is registered in 14 of 19 countries.
Countries holding a registration under ATC L01FD03 (trastuzumab emtansine), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Trastuzumab emtansine · ATC L01FD03
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of trastuzumab emtansine costs, country by country.
Normalised to the WHO defined daily dose (12 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Trastuzumab emtansine · price per daily dose (12 mg)
USD · FX 28 Sept 2026
- CH Switzerland$237.25
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Trastuzumab emtansine
- Manufacturer
- Originalis B.V.
- Country
- United Kingdom (GB)
- ATC code
- L01FD03
- ATC class
- Trastuzumab emtansine
- Defined daily dose
- 12 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin08719923004690
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
256 interactions on record for trastuzumab emtansine.
Graded by severity as the source publishes them — 62 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Trastuzumab emtansine · interactions on record
256 records
- 62 severe
- 194 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- DalteparinB01AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Trastuzumab emtansine in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainKADCYLA 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- FinlandKadcylaRoche Registration GmbH
- IrelandKadcyla 100 mg powder for concentrate for solution for infusionRoche Registration GmbH
- IcelandKadcylaRoche Registration GmbH*
- NorwayKadcylaRoche Registration GmbH
- PolandKadcylaRoche Registration GmbH
- BelgiumKadcyla 100 mgRoche Registration
- SwedenKadcyla 100 mg Pulver till koncentrat till infusionsvätska, lösningRoche Registration GmbH
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kadcyla
- Liechtenstein · Kadcyla
- Norway · Kadcyla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/770e898c-354b-4c1f-8c63-22daf990da2f GET /v1/drugs/770e898c-354b-4c1f-8c63-22daf990da2f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "38373411000001100",
"desc": "Kadcyla 100mg powder for concentrate for solution for infusion vials (Originalis B.V.)",
"form": "Powder for solution for infusion",
"vpid": "23985411000001104",
"source": "dmd",
"vtm_id": "896753000",
"strength": "100 mg",
"substance": "Trastuzumab emtansine",
"ingredient": "Trastuzumab emtansine",
"supplier_code": "36751511000001108"
}See everything about trastuzumab emtansine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.